The latest innovation to the PlasmaFlow portfolio. This is the only DVT device in the market that can be operated by a remote control. The device also features a best in class battery with a quick charge feature that allows the average charge time to be cut in half.
TAGS: PlasmaFlow, Venous Thromboembolism, Anticoagulants, Home Therapy, prevention of DVT, enhance blood circulation, stasis dermatitis, venous stasis ulcers, arterial and diabetic leg ulcers


  • Portable, lightweight and tubeless
  • Long lasting re-chargeable battery. Up to 10 hours of use on one charge
  • Quick Charge Feature. Full battery in less than 2.5 hours.
  • Remote control operation feature. The first in class.

  • 2 Modes: Slow inflation and Step-Up Technology which allows the unit to increase pressure in slower increments

  • Lowers Risk of Venous Thromboembolism (VTE): PlasmaFlow lowers incidence of VTE after major orthopedic surgery compared to pharmacological prophylaxis. VTE is the leading factor for hospital readmission following major orthopedic surgery and the most common preventable cause of hospital death.

  • Provides Possible Alternative to Anticoagulants: PlasmaFlow offers physicians another option to help tailor preventative care to patient risk and provides an alternative for patients contraindicated for anticoagulants.

  • Provides Convenient Home Therapy: As hospital stays continue to shorten, PlasmaFlow provides a solution for patients to take home and keep. This allows facilities to offer mechanical DVT prophylaxis for the 2-3 weeks patients need it most, without the hassle of renting or servicing equipment.

  • Lowers Total Cost: Bundled payment of care initiatives are driving single payment for an orthopedic episode within 30 days of surgery, including costly DVT readmissions. By reducing DVT-related expenses and potentially reducing costs for anticoagulant regimes or compression device rental programs, PlasmaFlow helps reduce the total cost of the episode.


Part # Description